Stock ALTHX THERANEXUS
Add to a list
To use this feature you must be a member
Log inSign up

All News Theranexus

Equities

ALTHX

FR0013286259

Market Closed - Euronext Paris
Other stock markets
 08:38:21 26/04/2024 pm IST 		5-day change 1st Jan Change
1.135 EUR +1.34% Intraday chart for Theranexus +8.10% +1.34%
19/04 Theranexus: share price rises following promising trial results CF
11/03 Theranexus: CEO takes over as Chairman of the Board CF

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Theranexus : Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
AT
Theranexus: share price rises following promising trial results
CF
Theranexus : Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
AT
Theranexus: CEO takes over as Chairman of the Board
CF
Theranexus : THERANEXUS ANNOUNCES APPOINTMENT OF MATHIEU CHARVÉRIAT AS BOARD OF DIRECTORS CHAIRMAN
AT
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2023 AND PRESENTS AN UPDATE ON ITS PROGRAMS
AT
Certain Ordinary Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 11-JAN-2024.
CI
Theranexus : THERANEXUS PUBLISHES ITS CASH POSITION AS OF 30 SEPTEMBER 2023
AT
Theranexus: promising results in Batten disease
CF
Theranexus : Theranexus : Highly Promising 12-month results in the Phase I/II trial of Batten-1
AT
Theranexus : THERANEXUS ANNOUNCES FIRST HALF 2023 FINANCIAL RESULTS
AT
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Theranexus : Theranexus raises around 3.1 million euros in fundraising
AT
Theranexus Société Anonyme announced that it has received €2.470412 million in funding
CI
Theranexus: share price rises on promising trials
CF
Theranexus : Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)
AT
Theranexus: EMA positive on Phase 3 design
CF
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital...
Our Logo
Erytech: renewed confidence in merger project
CF
Theranexus: FDA approval for Batten disease
CF
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALTHX Stock
  4. News Theranexus